ARArgenx ARGX · NASDAQ
$897.85 +0.68% (+$6.09)
- Market cap
- $55.8B
- Enterprise value
- $52.4B
- P/E
- 43.2x
- Forward P/E
- 33.9x
- PEG
- 0.8x
- P/S
- 13.4x
- P/FCF
- 66.1x
- EV/EBITDA
- 40.0x
- ROIC
- 14.5%
- Gross margin
- 89.1%
- Net margin
- 31.1%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -2.6x
- Beta
- -0.02
- Free float
- 99.8%
About the company
Argenx SE is a biopharmaceutical company based in Belgium, focusing on the development and commercialization of innovative therapies for the treatment of autoimmune diseases and malignant tumors. The company specializes in the development of monoclonal antibodies and utilizes its technology platform for the discovery and development of new drug candidates. Argenx focuses on therapeutic areas such as immunology, hematology, and oncology, aiming to provide potential treatments for patients with severe diseases who have limited therapeutic options available. The company also collaborates with pharmaceutical partners on the development and commercialization of its products. Argenx SE could be suitable for investors seeking opportunities in the biotechnology and pharmaceutical industries, with an emphasis on innovative therapies for the treatment of serious diseases.
Sector
Healthcare
Industry
Biotechnology
CEO
Karen Massey
Employees
1,863
Headquarters
Amsterdam
Valuation
Is today's price reasonable?
- What to watch: You pay 43.2 USD for 1 USD of yearly profit, a lot for its sector.
Growth and estimates
Is it growing, and what comes next?
- What speaks for it: Revenue grew by 116% a year over the last 3 years.
- What speaks for it: Analysts expect revenue to grow by 52% this fiscal year.
- What to watch: Earnings per share swing sharply from year to year.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What speaks for it: Out of every 100 USD of revenue, 31 USD is left as net profit.
Financial health
Can it carry its debt?
- What speaks for it: It holds more cash than debt: $3.58B against $47.0M.
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number